200 related articles for article (PubMed ID: 17439652)
1. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Meadows ES; Klein R; Rousculp MD; Smolen L; Ohsfeldt RL; Johnston JA
BMC Womens Health; 2007 Apr; 7():6. PubMed ID: 17439652
[TBL] [Abstract][Full Text] [Related]
2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Goeree R; Blackhouse G; Adachi J
Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
7. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.
Moriwaki K; Komaba H; Noto S; Yanagisawa S; Takiguchi T; Inoue H; Toujo T; Fukagawa M; Takahashi HE
J Bone Miner Res; 2013 Feb; 28(2):395-403. PubMed ID: 22991163
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
11. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.
Schousboe JT; Nyman JA; Kane RL; Ensrud KE
Ann Intern Med; 2005 May; 142(9):734-41. PubMed ID: 15867405
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
Christensen PM; Brixen K; Gyrd-Hansen D; Kristiansen IS
Basic Clin Pharmacol Toxicol; 2005 May; 96(5):387-96. PubMed ID: 15853932
[TBL] [Abstract][Full Text] [Related]
14. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
Meadows ES; Stock J; Johnston JA
Med Decis Making; 2006; 26(6):633-5; author reply 636-7. PubMed ID: 17099202
[No Abstract] [Full Text] [Related]
15. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Reginster JY
Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK
Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173
[TBL] [Abstract][Full Text] [Related]
19. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Buckley LM; Hillner BE
J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]